Wird geladen...

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the prese...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Park, Jin H., Liu, Yingting, Lemmon, Mark A., Radhakrishnan, Ravi
Format: Artigo
Sprache:Inglês
Veröffentlicht: Portland Press Ltd. 2012
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3507260/
https://ncbi.nlm.nih.gov/pubmed/23101586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BJ20121513
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!